UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):July 7, 2017
Aradigm Corporation
(Exact name of registrant as specified in its charter)
| | | | |
| California | | 001-36480 | | 94-3133088 |
| (State or other jurisdiction | | (Commission | | (I.R.S. Employer |
| of incorporation) | | File Number) | | Identification No.) |
| | | | |
| 3929 Point Eden Way, Hayward, California | | 94545 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(510)265-9000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| | ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| | ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 – Other Events.
On July 7, 2017, the Principal Investigator, Charles Haworth, MD, FRCP, for the Phase 3ORBIT-3 andORBIT-4 clinical trials (the “Studies”) of Aradigm Corporation (the “Company”) presented the analysis of the results for such trials, which investigated the safety and efficacy of the Company’s investigational drug product Linhaliq™, at the 2nd World Bronchiectasis Conference in Milan, Italy. Additionally, Igor Gonda, PhD, President and Chief Executive Officer of Aradigm, presented two posters on the Studies; the first poster presented additional microbiological results and the second presented pharmacokinetics results. All three presentations will be available on the Company’s website as soon as possible following the conference. The presentation abstracts are attached as Exhibit 99.1 to this Current Report on Form8-K and are incorporated herein by reference.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
| | |
Exhibit No. | | Document |
| |
| 99.1 | | Presentation abstracts on Phase 3ORBIT-3 andORBIT-4 clinical trials of Aradigm Corporation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | ARADIGM CORPORATION |
| | | |
| Dated: July 7, 2017 | | | | By: | | /s/ Nancy Pecota |
| | | | | | Name: | | Nancy Pecota |
| | | | | | Title: | | Vice President, Finance and Chief
Financial Officer and Corporate Secretary |
EXHIBIT INDEX
| | |
Exhibit No. | | Document |
| |
| 99.1 | | Presentation abstracts on Phase 3ORBIT-3 andORBIT-4 clinical trials of Aradigm Corporation |
